Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett profited massively from nervous markets. Here’s how!

With market turbulence making some investors nervous, our writer recalls several moments when Warren Buffett did well despite fearful markets.

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

How to target a 14%+ dividend yield by investing £10,000

There are many strategies for the average investor targeting a 14% dividend yield or higher. Our Foolish author explores one…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Up 6%, can this ‘gritty’ stock continue outperforming the rest of the FTSE 250?

ITV's share price is soaring as investors react to a resilient performance in 2025. The question is, can the FTSE…

Read more »

Investing Articles

How much income could £20k in a Stocks and Shares ISA give you today?

As the clock ticks on this year's Stocks and Shares ISA allowance, Harvey Jones looks at how investors could use…

Read more »

Investing Articles

What next for the Endeavour Mining share price after a record-breaking set of results?

Since March 2025, Endeavour Mining’s share price has risen 175%. Do the gold miner’s latest results provide any clues as…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

How are Rolls-Royce shares looking in March 2026?

March promises to be an interesting time for Rolls-Royce shares, but should investors be worried or calm about developments?

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

3 these stocks are smashing BAE Systems shares – are they worth considering today? 

Harvey Jones looks at the impact of current events on BAE Systems shares this week, and highlights some FTSE 100…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

At a forward P/E of 17, is Nvidia stock now a screaming buy?

Stephen Wright outlines why Nvidia stock could be better value now than it has been in a long time, despite…

Read more »